Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats
- 1 November 2015
- journal article
- Published by Elsevier in Behavioural Brain Research
- Vol. 294, 177-185
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress DisorderJAMA Psychiatry, 2014
- D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical TrialNeuropsychopharmacology, 2013
- Stress-induced metaplasticity: From synapses to behaviorNeuroscience, 2013
- GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side EffectsNeuropsychopharmacology, 2012
- A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autismNeuroscience & Biobehavioral Reviews, 2011
- Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSDNeuropsychopharmacology, 2007
- Social defeat, a paradigm of depression in rats that elicits 22-kHz vocalizations, preferentially activates the cholinergic signaling pathway in the periaqueductal grayBehavioural Brain Research, 2007
- Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorderJournal of Affective Disorders, 2006
- GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulatorNeuropharmacology, 2005
- The Gene Ontology (GO) database and informatics resourceNucleic Acids Research, 2004